Đang chuẩn bị liên kết để tải về tài liệu:
Vascular disrupting agent for neovascular age related macular degeneration: A pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD). | Vascular disrupting agent for neovascular age related macular degeneration: A pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

TÀI LIỆU LIÊN QUAN

Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model

Vascular disrupting agent for neovascular age related macular degeneration: A pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

Báo cáo y học: "Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines"

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells